• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Expert Ratings for NuVasive

    8/4/23 9:00:45 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care
    Get the next $NUVA alert in real time by email

    Over the past 3 months, 7 analysts have published their opinion on NuVasive (NASDAQ:NUVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 0 4 3 0 0
    Last 30D 0 1 0 0 0
    1M Ago 0 0 1 0 0
    2M Ago 0 0 0 0 0
    3M Ago 0 3 2 0 0

    In the last 3 months, 7 analysts have offered 12-month price targets for NuVasive. The company has an average price target of $52.0 with a high of $58.00 and a low of $40.00.

    Below is a summary of how these 7 analysts rated NuVasive over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

    price target chart

    This current average has increased by 6.34% from the previous average price target of $48.90.

    Stay up to date on NuVasive analyst ratings.

    What Are Analyst Ratings?

    Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

    Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

    If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $NUVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVA

    DatePrice TargetRatingAnalyst
    2/10/2023$57.72Overweight → Equal Weight
    Wells Fargo
    2/10/2023$63.00 → $52.00Buy → Neutral
    Citigroup
    2/10/2023$51.00 → $52.50Buy → Hold
    Truist
    1/6/2023Buy → Hold
    Needham
    10/18/2022$53.00Overweight
    Barclays
    10/12/2022$45.00Hold
    Jefferies
    4/13/2022$60.00 → $65.00Buy
    Truist
    3/28/2022$58.00Overweight
    Wells Fargo
    More analyst ratings

    $NUVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wolterman Dan

    4 - NUVASIVE INC (0001142596) (Issuer)

    9/5/23 5:06:55 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Raimundo Amy Belt

    4 - NUVASIVE INC (0001142596) (Issuer)

    9/5/23 5:04:52 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Norwalk Leslie V returned 3,095 shares to the company, closing all direct ownership in the company

    4 - NUVASIVE INC (0001142596) (Issuer)

    9/5/23 4:55:04 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    SEC Filings

    View All

    SEC Form 15-12G filed by NuVasive Inc.

    15-12G - NUVASIVE INC (0001142596) (Filer)

    9/11/23 4:46:57 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NuVasive Inc.

    EFFECT - NUVASIVE INC (0001142596) (Filer)

    9/8/23 12:15:09 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NuVasive Inc.

    EFFECT - NUVASIVE INC (0001142596) (Filer)

    9/8/23 12:15:14 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NuVasive downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded NuVasive from Overweight to Equal Weight and set a new price target of $57.72

    2/10/23 8:01:18 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    NuVasive downgraded by Citigroup with a new price target

    Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously

    2/10/23 7:45:41 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    NuVasive downgraded by Truist with a new price target

    Truist downgraded NuVasive from Buy to Hold and set a new price target of $52.50 from $51.00 previously

    2/10/23 7:45:03 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting

    SAN DIEGO, Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle.  "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especi

    8/30/23 7:00:00 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600

    NEW YORK, Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE:GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.Jackson Financial Inc. (NYSE:JXN) will replace NexTier Oilfield Solutions Inc. (NYSE:NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy Inc. (NASD: PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final cond

    8/28/23 5:41:00 PM ET
    $GMED
    $GSHD
    $JXN
    Medical/Dental Instruments
    Health Care
    Specialty Insurers
    Finance

    NuVasive Announces Second Quarter 2023 Financial Results

    –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

    8/2/23 4:05:00 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Leadership Updates

    Live Leadership Updates

    View All

    BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

    SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

    9/7/22 8:30:00 AM ET
    $AFIB
    $AVGR
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Blue Spark Technologies Announces Appointment of John DeFord, Ph.D. to its Board of Directors

    The new board member will provide extensive expertise to expand the TempTraq® remote patient monitoring platform Blue Spark Technologies Inc., a leader in wearable remote patient monitoring solutions, announced today the appointment of John DeFord, Ph.D. to its board of directors. Dr. DeFord's appointment, effective April 13th, 2022, brings the number of board members to five. "This is really an inflection point for the company and it's an exciting time to be involved. I look forward to helping mold the future of their technology," said Dr. DeFord. "I'm particularly excited to see the technology come together that will make an impact in patient's lives." "We are proud to welcome John to

    5/2/22 7:00:00 AM ET
    $NDSN
    $NUVA
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    NuVasive Appoints Andrew C. Morton as Chief Human Resources Officer

    SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022. Mr. Morton brings more than 25 years of experience in human resources, talent development, employee experience, and diversity and inclusion. As CHRO, Mr. Morton will oversee all human resources aspects of the Company

    1/31/22 4:10:00 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

    SC 13G/A - NUVASIVE INC (0001142596) (Subject)

    9/11/23 1:33:44 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by NuVasive Inc.

    SC 13G - NUVASIVE INC (0001142596) (Subject)

    2/13/23 3:58:05 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

    SC 13G/A - NUVASIVE INC (0001142596) (Subject)

    12/6/22 10:35:04 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    $NUVA
    Financials

    Live finance-specific insights

    View All

    NuVasive Announces Second Quarter 2023 Financial Results

    –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

    8/2/23 4:05:00 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results

    SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle

    7/24/23 7:00:00 AM ET
    $NUVA
    Medical/Dental Instruments
    Health Care

    NuVasive Announces First Quarter 2023 Financial Results

    –Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a

    5/10/23 4:05:00 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care